Cargando…
PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling
Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive breast cancer leads to improved survival, but resistance is a common clinical problem. To uncover novel mechanisms of resistance to anti-HER2 therapy in breast cancer, we performed a kinase open reading frame (ORF) screen t...
Autores principales: | Moody, Susan E., Schinzel, Anna C., Singh, Shambhavi, Izzo, Francesca, Strickland, Matthew R., Luo, Leo, Thomas, Sapana R., Boehm, Jesse S., Kim, So Young, Wang, Zhigang C., Hahn, William C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261061/ https://www.ncbi.nlm.nih.gov/pubmed/24909179 http://dx.doi.org/10.1038/onc.2014.153 |
Ejemplares similares
-
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors
por: Goh, Gerald, et al.
Publicado: (2014) -
PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors
por: Berthon, Annabel S., et al.
Publicado: (2015) -
Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma
por: Tomasini, Michael D., et al.
Publicado: (2018) -
Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA
por: Neumayer, Christoph, et al.
Publicado: (2023) -
DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma
por: Vyas, Monika, et al.
Publicado: (2019)